化學(xué)制劑分次給藥對(duì)卵巢癌細(xì)胞種群恢復(fù)的影響及其在鉑類耐藥型復(fù)發(fā)卵巢癌患者中的療效觀察
[Abstract]:Aim: to compare the effects of different regimen of cisplatin (Cisplatin,CDDP) and paclitaxel (Paclitaxel,PTX) on SKOV3 population recovery in ovarian cancer cells. The efficacy of the two cytotoxic agents in patients with recurrent platinum resistance and refractory ovarian cancer was observed. Method 1: 1. The effects of CDDP and / or PTX on apoptosis and population recovery of SKOV3 cells were observed by inverted microscope, and the absorbance values (Optical density,OD) of D7 and D21 were measured by CCK-8 method. Twenty patients with recurrent platinum-resistant and refractory ovarian cancer were treated with CDDP90mg/m2 as D _ 1, D _ 2, D _ 3 PTX175mg/m2 as D _ 1 and D _ 8 regimen chemotherapy. The changes of symptoms, signs, imaging examination and CA125 before and after treatment were analyzed. To evaluate the chemotherapeutic reactivity of these patients and to explore the clinical value of the regimen. Results: there was no significant difference in the effect of single or partial administration of 11.1CDDP on the apoptosis and population recovery of SKOV3 (FF70.421 P0. 970), 1.2 the single administration of PTX and CDDP combined with PTX significantly inhibited the population recovery of SKOV3 cells (FN 1872. 275 p0. 000). The inhibitory effect was more obvious in the combined treatment group than in the combination group. 22.1 the response of 20 patients with recurrent platinum-resistant and refractory ovarian cancer to CDDP90mg/m2 as D _ 1, D _ 2, D _ 3 PTX175mg/m2 divided into D _ 1 and D _ 8 was observed, and the inhibitory effect was more significant in the combination group (F _ (250) 0.464 (P _ (0.000), 22.1 the response of 20 patients with recurrent platinum resistance and refractory ovarian cancer to D1, D _ 2, D _ 3 PTX175mg/m2 was observed. The results showed that the response rate was 75% (15 / 20), and the complete remission rate was 25% (5 / 20), 2.2 the main adverse reactions of the regimen were bone marrow depression and gastrointestinal reaction. Conclusion: cytological results suggest that CDDP combined with PTX can significantly inhibit the population recovery of ovarian cancer SKOV3 cells. For patients with recurrent platinum resistance and refractory ovarian cancer, the combination of the two drugs can obtain better reactivity, but the specific mechanism and the improvement of the survival of the patients need to be further discussed and observed.
【學(xué)位授予單位】:重慶醫(yī)科大學(xué)
【學(xué)位級(jí)別】:碩士
【學(xué)位授予年份】:2014
【分類號(hào)】:R737.31
【相似文獻(xiàn)】
相關(guān)期刊論文 前10條
1 孟嵐,馬玉蘭,鄒風(fēng)華;硫噴妥鈉分次給藥伍用芬太尼減輕氣管插管對(duì)心血管副反應(yīng)(摘要)[J];康復(fù)與療養(yǎng)雜志;1996年01期
2 周炬;;分次給藥法可加速潘可朗寧起效時(shí)間[J];國外醫(yī)學(xué).麻醉學(xué)與復(fù)蘇分冊(cè);1986年02期
3 王虹;程紅;;分次給藥法預(yù)防多西他賽過敏反應(yīng)的效果觀察[J];護(hù)理學(xué)雜志;2009年19期
4 徐寅;周崢;;紫杉醇分次給藥法減輕乳腺癌患者過敏反應(yīng)的觀察[J];護(hù)理學(xué)報(bào);2008年09期
5 趙勇;;合理應(yīng)用時(shí)間、濃度依賴性抗菌藥物[J];實(shí)用藥物與臨床;2006年05期
6 王裕珍,李f^,陶瑛;肝動(dòng)脈門靜脈插管灌注治療肝癌的護(hù)理[J];護(hù)士進(jìn)修雜志;1994年02期
7 邱梅俊;;穿破硬膜后頭痛的防治體會(huì)[J];中國實(shí)用醫(yī)藥;2011年24期
8 施小彤,譚冠先,藍(lán)雨雁,胡振快;異丙酚用于全麻誘導(dǎo)的臨床效果觀察[J];廣東醫(yī)學(xué);2001年08期
9 童淑惠,李海味;術(shù)前口服西洋參影響麻醉效果的觀察(摘要)[J];海峽藥學(xué);1994年03期
10 ;[J];;年期
相關(guān)碩士學(xué)位論文 前1條
1 何歡;化學(xué)制劑分次給藥對(duì)卵巢癌細(xì)胞種群恢復(fù)的影響及其在鉑類耐藥型復(fù)發(fā)卵巢癌患者中的療效觀察[D];重慶醫(yī)科大學(xué);2014年
本文編號(hào):2263167
本文鏈接:http://www.sikaile.net/yixuelunwen/fuchankeerkelunwen/2263167.html